



Biomédica

ISSN: 0120-4157

biomedica@ins.gov.co

Instituto Nacional de Salud

Colombia

Vega, Jorge A.; Villegas-Ospina, Simón; Aguilar-Jiménez, Wbeimar; Rugeles, María T.;  
Bedoya, Gabriel; Zapata, Wildeman  
Haplotypes in CCR5-CCR2, CCL3 and CCL5 are associated with natural resistance to  
HIV-1 infection in a Colombian cohort  
Biomédica, vol. 37, núm. 2, 2017, pp. 267-273  
Instituto Nacional de Salud  
Bogotá, Colombia

Available in: <http://www.redalyc.org/articulo.oa?id=84350981017>

- How to cite
- Complete issue
- More information about this article
- Journal's homepage in redalyc.org

redalyc.org

Scientific Information System

Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal

Non-profit academic project, developed under the open access initiative

BRIEF COMMUNICATION

## Haplotypes in *CCR5-CCR2*, *CCL3* and *CCL5* are associated with natural resistance to HIV-1 infection in a Colombian cohort

Jorge A. Vega<sup>1,2,3</sup>, Simón Villegas-Ospina<sup>1</sup>, Wbeimar Aguilar-Jiménez<sup>1</sup>,  
María T. Rugeles<sup>1</sup>, Gabriel Bedoya<sup>3</sup>, Wildeman Zapata<sup>1,4</sup>

<sup>1</sup> Grupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia

<sup>2</sup> Laboratorio de Genética, Dirección Regional Noroccidente, Instituto Nacional de Medicina Legal y Ciencias Forenses, Medellín, Colombia

<sup>3</sup> Genética Molecular, Instituto de Biología, Universidad de Antioquia, Medellín, Colombia

<sup>4</sup> Grupo Infettare, Facultad de Medicina, Universidad Cooperativa de Colombia, Medellín, Colombia

**Introduction:** Variants in genes encoding for HIV-1 co-receptors and their natural ligands have been individually associated to natural resistance to HIV-1 infection. However, the simultaneous presence of these variants has been poorly studied.

**Objective:** To evaluate the association of single and multilocus haplotypes in genes coding for the viral co-receptors *CCR5* and *CCR2*, and their ligands *CCL3* and *CCL5*, with resistance or susceptibility to HIV-1 infection.

**Materials and methods:** Nine variants in *CCR5-CCR2*, two SNPs in *CCL3* and two in *CCL5* were genotyped by PCR-RFLP in 35 seropositive (cases) and 49 HIV-1-exposed seronegative Colombian individuals (controls). Haplotypes were inferred using the Arlequin software, and their frequency in individual or combined loci was compared between cases and controls by the chi-square test. A *p* value <0.05 after Bonferroni correction was considered significant.

**Results:** Homozygosis of the human haplogroup (HH) E was absent in controls and frequent in cases, showing a tendency to susceptibility. The haplotypes C-C and T-T in *CCL3* were associated with susceptibility (*p*=0.016) and resistance (*p*<0.0001) to HIV-1 infection, respectively. Finally, in multilocus analysis, the haplotype combinations formed by HHC in *CCR5-CCR2*, T-T in *CCL3* and G-C in *CCL5* were associated with resistance (*p*=0.006).

**Conclusion:** Our results suggest that specific combinations of variants in genes from the same signaling pathway can define an HIV-1 resistant phenotype. Despite our small sample size, our statistically significant associations suggest strong effects; however, these results should be further validated in larger cohorts.

**Key words:** HIV-1; immunity, innate; phenotype; haplotypes; Colombia.

doi: <http://dx.doi.org/10.7705/biomedica.v37i3.3237>

### Los haplotipos en *CCR5-CCR2*, *CCL3* y *CCL5* se asocian con resistencia natural a la infección por el HIV-1 en una cohorte colombiana

**Introducción.** Algunas variantes en genes que codifican los correceptores del HIV-1 y sus ligandos se han asociado individualmente a la resistencia natural frente a dicha infección. Sin embargo, su presencia simultánea ha sido poco estudiada.

**Objetivo.** Evaluar la asociación de haplotipos individuales y multilocus en genes que codifican los correceptores virales *CCR5* y *CCR2* y sus ligandos *CCL3* y *CCL5* con la resistencia o la propensión a la infección por el HIV-1.

**Materiales y métodos.** Nueve variantes en *CCR5-CCR2*, dos en *CCL3* y dos en *CCL5* fueron genotipificadas mediante reacción en cadena de la polimerasa de polimorfismos de longitud de fragmentos de restricción (*Restriction Fragment Length Polymorphism*-PCR-RFLP) en 35 individuos seropositivos (casos) y 49 seronegativos expuestos (controles) de Colombia. Los haplotipos se infirieron utilizando el programa Arlequín, y su frecuencia individual o combinada se comparó en los casos y los controles mediante la prueba de ji al cuadrado. Se consideró significativo un valor de *p*<0,05 después de la corrección de Bonferroni.

#### Author's contributions:

María T. Rugeles: conception and design of experiments

Gabriel Bedoya: conception and design of experiments; data analysis

Jorge A. Vega: conduction of experiments and data analysis

Simón Villegas-Ospina, Wbeimar Aguilar-Jiménez, Wildeman Zapata: data analysis and results interpretation

All authors participated in the writing of the paper.

**Resultados.** La homocigosis del haplogrupo humano (HH) E estaba ausente en los controles y era frecuente en los casos, es decir, con tendencia hacia la propensión. Los haplotipos C-C y T-T en *CCL3* se asociaron con la propensión ( $p'=0,016$ ) y la resistencia ( $p'<0,0001$ ), respectivamente. Por último, en el análisis multilocus, el haplotipo combinado formado por HHC en *CCR5-CCR2*, T-T en *CCL3* y G-C en *CCL5* se asoció con la resistencia ( $p'=0,006$ ).

**Conclusión.** Los resultados de este estudio sugieren que ciertas combinaciones específicas de variantes en los genes de una misma vía de señalización pueden definir un fenotipo resistente al HIV-1. Aunque el tamaño de la muestra era pequeño, las asociaciones estadísticamente significativas sugieren un efecto considerable; sin embargo, estos resultados deben validarse en cohortes de mayor tamaño.

**Palabras clave:** HIV-1, inmunidad innata; fenotipo; haplotipos; Colombia.

doi: <http://dx.doi.org/10.7705/biomedica.v37i3.3237>

Natural resistance to HIV-1 infection exhibited by some individuals who, despite being in direct contact with the virus, show no evidence of infection (known as HIV-1-exposed seronegative, HESN) has been associated, among others, to polymorphisms in genes that encode the HIV-1 co-receptors CCR5 and CXCR4, as well as the alternative co-receptor CCR2 (1).

Seven major haplotypes have been described based on unique combinations of polymorphic sites in *CCR5* and the adjacent *CCR2* gene, which were phylogenetically established and named as human haplogroups (HH) A, B, C, D, E, F (F1, F2) and G (G1, G2)(2,3). Some of these have been associated with either resistance (HHG2, HHA, HHF2) (2,4,5) or increased susceptibility to HIV-1 infection and accelerated AIDS progression (HHE) (6-8). Furthermore, polymorphisms located in promoter or intronic regions of the natural ligands of CCR5, *CCL3* (also known as MIP-1 $\alpha$ , encoded by *CCL3*) and *CCL5* (also known as RANTES, encoded by *CCL5*) could modify the secretion levels of these peptides further influencing the resistance or susceptibility (R/S) to HIV-1 infection by competition with the CCR5 co-receptor (3).

In this study, we determined the association of multilocus haplotypes formed by variants on the promoter and coding regions of the *CCR5-CCR2* locus, and the *CCL3* and *CCL5* genes with R/S to HIV-1 infection in a cohort of serodiscordant couples from Colombia.

## Materials and methods

### Study group

Samples were taken from a cohort of serodiscordant couples previously recruited at the *Hospital San Vicente Fundación* in Medellín that included 49 (17 men, 32 women) HESNs and 35 (31 men, four women) seropositive (SP) individuals. The selection criteria for HESNs were previously described (9) as absence of anti-p24 antibodies during at least six months of follow-up, in which at least two sexual intercourse occurred per week with an HIV-1 positive individual. For all cases, the HIV-1 status was tested by ELISA (Abbot AxSYM System) and confirmed through western blot (NewLab blot) following the manufacturer's instructions.

This study was approved by the bioethics board of the *Universidad de Antioquia's Instituto de Investigaciones Médicas* and all participants signed an informed consent.

### Genotype analysis

DNA was obtained from peripheral blood using the phenol-chloroform method. The genotyping of the 32-base-pair deletion ( $\Delta 32$ , rs333) on *CCR5* was performed by conventional PCR as previously described (9). The identification of SNPs in the selected genes (-2733A>G [rs2856758], -2554G>T [rs2734648], -2459G>A [rs1799987], -2135T>C [rs1799988], -2132C>T [rs41469351], -2086A>G [rs1800023] and -1835C>T [rs1800024] in *CCR5*; 190G>A [64Val>Ile, rs1799864] in *CCR2*; 73+40C>T [rs35511254] and 74-333C>T [rs111235874] in *CCL3*; -403G>A [rs2107538] and -28C>G [rs2280788] in *CCL5*) was performed by PCR-RFLP using the oligonucleotides, restriction enzymes and protocols previously reported by González, *et al.* (2,3). PCR reactions were performed on 25  $\mu$ l final mix containing 2.5  $\mu$ l 10X reaction buffer (Thermo Scientific, St. Leon-Rot, Germany), 0.2  $\mu$ l recombinant Taq polymerase 5 IU/ $\mu$ l (Thermo

Corresponding author:

Wildeman Zapata, Grupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia, Calle 70 N° 52-21, Medellín, Colombia  
Telephone/Fax: (574) 219 6482  
wzbuiles@gmail.com

Received: 11/02/16; accepted: 29/09/16

Scientific), 1 µl primers 25 mM and 2 µl DNA 8 µg/ml. Endonuclease digestion was performed on 13 µl of amplification products with 0.2 µl restriction endonucleases 10 IU/µl (Thermo Scientific) and 1.5 µl 10X reaction buffer (Thermo Scientific) following the protocols reported by González, *et al.* (2,3). PCR and endonuclease digestion products were checked on 1.5% and 2.5% agarose gels, respectively.

### Statistical analysis

Hardy-Weinberg equilibrium and genotype and allele frequencies were calculated using the GENPOP software, v. 3.4 (10). Most probable haplotypes were generated through a maximum likelihood test using the Arlequin software, v. 3.5(11) and haplogroups were defined according to previous reports (2,5). The DnaSP software v.5 (12) was used to calculate linkage disequilibrium and haplotype frequencies. All comparisons were performed in the Graphpad Prism 6.05 software using either the chi-square or the Fisher exact test, both with Bonferroni correction for multiple comparisons (referred to as  $p'$ ), based on the number of principal haplotypes (with a frequency  $>0.05$ ) as previously described (13). A corrected  $p'$  value ( $p \times \text{number of comparisons per group}$ )  $<0.05$  was considered statistically significant.

## Results

### Demographic data

In this study we included samples from 49 HESN and 35 SP individuals of a previously defined cohort of serodiscordant couples (including heterosexual and homosexual couples, as well as SP individuals with more than one HESN sexual partner). In our samples, 17 males and 32 females corresponded to the HESN group, whereas 31 males and four females corresponded to the SP group. The mean age was 35 and 31 years for HESN and SP, respectively. The time of HIV-1 exposure among HESN individuals ranged between six months and four years. No genetic structure between cases and controls was expected, as the population was recruited in Medellín, whose population has been previously demonstrated to be homogeneous given its history of isolation (14,15).

### Haplotype distribution

The selected loci on *CCR5* and *CCR2* successfully genotyped in all individuals of our cohort. These variants were successfully grouped within the nine previously reported HHs. Of all HHs, only HHB was not found in this study. In total, we found 21 out of 36 expected haplogroup pairs (binomial coefficient  $C_{(8,2)}$ ), with the presence of 14 and 17 pairs in the

SP and HESN groups, respectively, C/E being the most frequent in both groups (0.257 for SPs and 0.265 for HESNs) (table 1).

For the two polymorphic sites of *CCL3*, only 18 and 21 samples successfully amplified both SNPs in HESNs and SPs, respectively. For these, the four possible haplotypes (2 loci  $\times$  2 variants in each) and seven out of ten expected haplotype pairs ( $C_{(4,2)}$ ) were observed in total, with four and five pairs in the SP and HESN groups, respectively. For the two polymorphic sites in *CCL5*, only 14 and 19 samples successfully amplified both SNPs in HESNs and SPs, respectively. For these, the four possible haplotypes and five out of ten expected haplotype pairs were observed in total, with four and five pairs found in the SP and HESN groups, respectively (table1).

To determine the combined association of variants in HHs, *CCL5* and *CCL3* with R/S, a multilocus analysis was performed. Nonetheless, we could only use 14 samples in HESNs and 19 in SPs that successfully amplified and enzyme-digested the 13 tested loci. For this multilocus combination of HH, *CCL3* and *CCL5*, we found 26 haplotypes and 22 haplotype pairs in total, with ten haplotypes and 12 pairs in HESNs and 16 haplotypes and 15 pairs in SPs, out of 128 expected haplotypes ( $8_{HH} \times 4_{CCL3} \times 4_{CCL5}$ ) and 805 expected pairs ( $23_{HH} \times 7_{CCL3} \times 5_{CCL5}$ ) (table 2).

### Association analysis

Whereas none of the HHs were individually associated with R/S to HIV-1 infection, homozygosity of HHE (E/E) was only found in infected individuals, showing a non-significant tendency towards susceptibility ( $p=0.069$ ,  $p'>1$ ). For *CCL3*, the haplotype C-C was higher in SPs ( $p=0.004$ ,  $p'=0.016$ ) while haplotype T-T was higher in HESNs ( $p<0.0001$ ,  $p'<0.0001$ ). When paired, the combination CT-CC was associated with susceptibility ( $p=0.035$ ,  $p'=0.245$ ), whereas CT-TT was associated with resistance ( $p=0.002$ ,  $p'=0.014$ ). For *CCL5*, no significant differences were found for either haplotypes or pairs of haplotypes. After multilocus analysis we observed that the simultaneous presence of HHC with T-T in *CCL3* and G-C in *CCL5* was strongly associated with resistance to infection ( $p=0.0005$ ,  $p'=0.006$ ), and so was the paired combination of HHC/F2 with TT-TT in *CCL3* and AG-CC in *CCL5*; however, this latter situation did not remain significant after Bonferroni correction ( $p=0.040$ ,  $p'=0.880$ ). These results are summarized in table 3.

**Table 1.** Frequencies obtained for single locus analyses. Left columns indicate the frequency of the single copy of a given haplotype, whereas the right columns indicate the frequency of paired haplotypes. Haplotypes marked in bold reached statistical significance before Bonferroni correction.

Single haplotype copy		Freq. in SP	Freq. in HESN	Paired haplotype		Freq. in SP	Freq. in HESN
HH		n=35	n=49			n=35	n=49
A		0.014	0.020	A/C		0.028	0.021
B		0.000	0.000	A/E		0.000	0.021
C		0.243	0.337	C/C		0.028	0.062
D		0.071	0.020	C/D		0.057	0.000
E		0.314	0.245	C/E		0.257	0.265
F1		0.000	0.020	C/F2		0.057	0.164
F2		0.243	0.235	C/G1		0.000	0.041
G1		0.086	0.071	C/G2		0.028	0.041
G2		0.023	0.051	D/E		0.000	0.021
				D/F2		0.086	0.021
				E/E		0.086	0.000
				E/F1		0.000	0.021
				E/F2		0.143	0.122
				E/G1		0.057	0.041
				F1/F2		0.000	0.021
				F2/F2		0.057	0.062
				F2/G1		0.057	0.021
				F2/G2		0.028	0.000
				G1/G1		0.028	0.000
				G1/G2		0.000	0.021
				G2/G2		0.000	0.021
<b>CCL3</b>		n=21	n=18			n=21	n=18
<b>73+40</b>	<b>74-333</b>			<b>73+40</b>	<b>74-333</b>		
<b>C&gt;T</b>	<b>C&gt;T</b>			<b>C&gt;T</b>	<b>C&gt;T</b>		
<b>C</b>	<b>C</b>	<b>0.476</b>	<b>0.172</b>	<b>CT</b>	<b>CC</b>	<b>0.619</b>	<b>0.278</b>
C	T	0.143	0.217	TT	TT	0.000	0.167
T	C	0.381	0.217	<b>CT</b>	<b>TT</b>	<b>0.000</b>	<b>0.389</b>
<b>T</b>	<b>T</b>	<b>0.000</b>	<b>0.394</b>	CT	CT	0.143	0.111
				TT	CC	0.000	0.056
				CC	CT	0.143	0.000
				CC	CC	0.095	0.000
<b>CCL5</b>		n=19	n=14			N=19	N=14
<b>-403</b>	<b>-28</b>			<b>-403</b>	<b>-28</b>		
<b>A&gt;G</b>	<b>C&gt;G</b>			<b>A&gt;G</b>	<b>C&gt;G</b>		
A	C	0.132	0.286	AG	CC	0.211	0.500
A	G	0.079	0.071	AG	GG	0.000	0.071
G	C	0.658	0.571	AG	GC	0.211	0.143
G	G	0.132	0.071	GG	CG	0.211	0.071
				GG	CC	0.368	0.214

HH: human haplogroup; CCL3: C-C motif ligand 3; CCL5: C-C motif ligand 5; SP: HIV-1 seropositive; HESN: HIV-1 exposed seronegative

## Discussion

An important component involved in the R/S to HIV-1 infection is the expression levels of the CCR5 co-receptor on the cell. Previous studies have shown that several members of the NF- $\kappa$ B and c-Rel families have different binding and affinity across the CCR5 promoter region depending of both single SNPs and whole CCR5 HH, which regulate in different ways the mRNA levels, translation capacity and, ultimately, protein expression (16). Indeed, previous findings have shown that HHE has a higher promoter activity than

the ancestral and protective HHA, as measured by the luciferase activity test (17,18), leading to higher expression of CCR5 in individuals carrying HHE.

Although not significant after Bonferroni correction, probably due to our small sample size, our finding concerning HH E/E pointing towards susceptibility to HIV-1 infection is in concordance with previous studies showing an association with seroconversion and progression to AIDS (2,7,19), and could be explained by the expected higher expression of CCR5. An interesting point is that the susceptibility-associated effect of the HHE



**Table 2.** Frequencies obtained for multilocus haplotype analyses. Left columns indicate the frequency of the single copy of a given multilocus haplotype, whereas right columns indicate the frequency of paired multilocus haplotypes. Haplotypes marked in bold reached statistical significance before Bonferroni correction.

Single haplotype copy					Freq. in SP	Freq. in HESN	Paired haplotype				Freq. in SP	Freq. in HESN	
HH	CCL3		CCL5		n=19	n=14	HH	CCL3		CCL5		n=19	n=14
	73+40 C>T	74-333 C>T	-403 A>G	-28 C>G				73+40 C>T	74-333 C>T	-403 A>G	-28 C>G		
A	C	T	G	C	0.029	0.000	C/F2	CT	CT	AG	CC	0.053	0.067
C	T	C	A	C	0.002	0.000	<b>C/F2</b>	<b>TT</b>	<b>TT</b>	<b>AG</b>	<b>CC</b>	<b>0.000</b>	<b>0.268</b>
C	C	C	G	C	0.061	0.115	C/E	CT	CC	GG	CC	0.158	0.067
C	T	C	G	C	0.114	0.000	C/E	CT	TT	AG	GC	0.000	0.067
D	T	C	G	C	0.029	0.000	C/E	CT	TT	GG	CC	0.000	0.067
E	T	T	A	C	0.029	0.000	C/F2	CT	CT	AG	GC	0.000	0.067
E	T	C	A	G	0.088	0.000	G1/G2	CT	CC	GG	GC	0.000	0.067
E	T	T	A	G	0.029	0.000	E/F2	CT	CC	AG	GC	0.158	0.067
E	C	C	G	C	0.147	0.000	C/C	CT	TT	AG	CC	0.000	0.200
E	C	T	G	G	0.029	0.000	C/C	CT	CT	GG	CC	0.000	0.067
F2	C	C	A	C	0.057	0.000	C/F2	CT	CC	GG	CC	0.053	0.000
F2	C	C	G	C	0.235	0.000	G1/G1	CC	CT	AG	CC	0.053	0.000
F2	T	C	G	C	0.031	0.000	F2/F2	CC	CC	AG	CC	0.053	0.000
G1	C	T	A	C	0.029	0.000	F2/G1	CC	CC	GG	CC	0.053	0.000
G1	C	C	G	C	0.059	0.038	E/E	CT	CT	AG	GC	0.053	0.000
G1	T	C	G	G	0.029	0.000	E/G1	CT	CC	GG	GC	0.053	0.000
C	C	T	A	C	0.000	0.077	C/E	CT	CC	AG	GC	0.053	0.000
C	C	T	A	G	0.000	0.038	F2/F2	CT	CC	GG	CC	0.053	0.000
<b>C</b>	<b>T</b>	<b>T</b>	<b>G</b>	<b>C</b>	<b>0.000</b>	<b>0.308</b>	D/F2	CT	CC	GG	CC	0.053	0.000
E	C	T	G	C	0.000	0.038	E/E	CT	CT	AG	CC	0.053	0.000
E	T	C	G	C	0.000	0.077	A/C	CC	CT	GG	CC	0.053	0.000
E	T	T	G	G	0.000	0.038	E/F2	CC	CT	GG	GC	0.053	0.000
F2	T	C	A	C	0.000	0.038							
F2	T	T	A	C	0.000	0.115							
F2	C	C	A	G	0.000	0.077							
G2	T	C	G	G	0.000	0.038							

HH: human haplogroup; CCL3: C-C motif ligand 3; CCL5: C-C motif ligand 5; SP: HIV-1 seropositive; HESN: HIV-1 exposed seronegative

**Table 3.** Summary of single and multilocus haplotypes and pairs of haplotypes that reached statistical significance, both before and after Bonferroni correction. Frequencies in bold show the associated group, thus indicating susceptibility or resistance towards infection.

					Frequency		p-value	p'-value
					SP	HESN		
<b>CCL3</b>								
<b>73+40C&gt;T</b>	<b>74-333C&gt;T</b>							
T	T				0.000	<b>0.394</b>	< 0.0001	<0.0001
C	C				<b>0.476</b>	0.172	0.004	0.016
CT	TT				0.000	<b>0.111</b>	0.002	0.014
CT	CC				<b>0.619</b>	0.278	0.035	0.245
HH								
	<b>CCL3</b>		<b>CCL5</b>					
	<b>73+40C&gt;T</b>	<b>74-333C&gt;T</b>	<b>-403A&gt;G</b>	<b>-28C&gt;G</b>				
C	T	T	G	C	0.000	<b>0.308</b>	0.0005	0.006
C/F2	TT	TT	AG	CC	0.000	<b>0.231</b>	0.040	0.880

SP: HIV-1 seropositive; HESN: HIV-1 exposed seronegative; HH: human haplogroup; CCL3: C-C motif ligand 3; CCL5: C-C motif ligand 5

has also been reported when paired with HHG2, leading to increased viral production *in vitro*, even though the latter carries the  $\Delta 32$  mutation, possibly

due to restitution of the normal CCR5 levels over the cell membrane (20). Nevertheless, HHG2 has been effectively associated with protection and

decreased seroconversion when found in the homozygous state, or when paired with either HHA or HHF2 (19). These findings suggest that for HHs, the association with R/S depends on the effect of both copies carried by an individual over the overall expression of CCR5 on the cell membrane.

Our results regarding *CCL3*, where the T-T haplotype was associated with resistance and C-C with increased risk, contrast with previous reports where the presence of both C-C and T-T haplotypes were associated with resistance in Africans, whereas the absence of haplotype C-C in European Americans was associated to AIDS progression (3). Different ancestral backgrounds might be affecting how these variants synergize during exposure and infection. This becomes important since the Colombian population originated through admixture processes of Amerindian, European and African populations (14); therefore, a new genetic background might explain these results.

Even though we did not find an association in *CCL5* alone, as was previously reported (3), we did find an interesting association when variants in *CCR5*/*CCR2*, *CCL3* and *CCL5* were analyzed together, with the multilocus haplotype formed by HHC, T-T in *CCL3* and G-C in *CCL5* associated with resistance. Although two meta-analyses (21,22), with only one single variant in *CCL5* analyzed, have reported no association of any of them with R/S, our findings suggest that the simultaneous presence of variants on different genes involved in a common signaling or metabolic pathway (receptor and its ligands, in our case) can lead to a certain resistant or susceptible phenotype, probably due to the synergistic effect of these variants. We thus hypothesize that the resistance to viral infection in these cases might be due to the low expression of the viral specific co-receptors and high levels of their natural ligands competing for its use, and vice-versa, in the susceptible phenotype. However, as reviewed recently (23), functional studies are required to validate the function of intronic and promoter variants in *CCL3* and *CCL5* mRNA levels and stability and of the secretion of MIP-1 $\alpha$  and RANTES, as no data concerning these effects is available.

Despite the small sample size, mainly because of the exploratory characteristics of this study, the statistically significant results obtained here, even after the correction for multiple comparisons, support the accuracy of our results and suggest strong effects. Careful observations should, however, be considered, especially since the sample size of the

*CCL3*, *CCL5* and multilocus analyses fell short due to poor amplification products. Finally, to increase the strength of this study, our results should be validated in larger cohorts.

### Aknowledgements

The authors would like to thank all individuals who participated in this study, and Anne-Lise Haenni from the Université Paris-Diderot for her positive revision and English proof-reading.

### Conflicts of interest

The authors declare that they have no conflicts of interest. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

### Funding

This work was supported by the *Universidad de Antioquia*, Colombia (*Sostenibilidad Grupo GENMOL and Grupo Inmunovirología*), and *Universidad Cooperativa de Colombia* (*Sostenibilidad 2014-2016, Grupo Infettare*).

### References

1. Frade JM, Llorente M, Mellado M, Alcamí J, Gutiérrez-Ramos JC, Zaballos A, et al. The amino-terminal domain of the CCR2 chemokine receptor acts as coreceptor for HIV-1 infection. *J Clin Invest*. 1997;100:497-502. <http://dx.doi.org/10.1172/JCI119558>
2. González E, Bamshad M, Sato N, Mummidi S, Dhanda R, Catano G, et al. Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. *Proc Natl Acad Sci USA*. 1999;96:12004-9. <http://dx.doi.org/10.1073/pnas.96.21.12004>
3. González E, Dhanda R, Bamshad M, Mummidi S, Geevarghese R, Catano G, et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1  $\alpha$ : Impact on the epidemiology of the HIV-1 pandemic. *Proc Natl Acad Sci U S A*. 2001;98:5199-204. <http://dx.doi.org/10.1073/pnas.091056898>
4. Ometto L, Zanchetta M, Mainardi M, De Salvo GL, García-Rodríguez MC, Gray L, et al. Co-receptor usage of HIV-1 primary isolates, viral burden, and CCR5 genotype in mother-to-child HIV-1 transmission. *AIDS*. 2000;14:1721-9.
5. Zapata W, Aguilar-Jiménez W, Pineda-Trujillo N, Rojas W, Estrada H, Rugeles MT. Influence of CCR5 and CCR2 genetic variants in the resistance/susceptibility to HIV in serodiscordant couples from Colombia. *AIDS Res Hum Retroviruses*. 2013;29:1594-603. <http://dx.doi.org/10.1089/aid.2012.0299>
6. Singh KK, Barroga CF, Hughes MD, Chen J, Raskino C, McKinney RE, et al. Genetic influence of CCR5, CCR2, and SDF1 variants on human immunodeficiency virus 1 (HIV-1)-related disease progression and neurological impairment, in children with symptomatic HIV-1 infection. *J Infect Dis*. 2003;188:1461-72. <http://dx.doi.org/10.1086/379038>

7. **Nguyen L, Li M, Chaowanachan T, Hu DJ, Vanichseni S, Mock PA, et al.** CCR5 promoter human haplogroups associated with HIV-1 disease progression in Thai injection drug users. *AIDS*. 2004;18:1327-33. <http://dx.doi.org/10.1097/01.aids.0000131303.39957.15>
8. **Li M, Song R, Masciotra S, Soriano V, Spira TJ, Lal RB, et al.** Association of CCR5 human haplogroup E with rapid HIV type 1 disease progression. *AIDS Res Hum Retroviruses*. 2005;21:111-5. <http://dx.doi.org/10.1089/aid.2005.21.111>
9. **Rugeles MT, Solano F, Díaz FJ, Bedoya VI, Patiño PJ.** Molecular characterization of the CCR 5 gene in seronegative individuals exposed to human immunodeficiency virus (HIV). *J Clin Virol*. 2002;23:161-9. [http://dx.doi.org/10.1016/S1386-6532\(01\)00219-0](http://dx.doi.org/10.1016/S1386-6532(01)00219-0)
10. **Rousset F.** Genepop'007: A complete reimplementation of the Genepop software for Windows and Linux. *Mol Ecol Resour*. 2008;8:103-6. <http://dx.doi.org/10.1111/j.1471-8286.2007.01931.x>
11. **Excoffier L, Lischer H.** Arlequin suite ver 3.5: A new series of programs to perform population genetics analyses under Linux and Windows. *Mol Ecol Resour*. 2010;10:564-7. <http://dx.doi.org/10.1111/j.1755-0998.2010.02847.x>
12. **Librado P, Rozas J.** DnaSP v5: A software for comprehensive analysis of DNA polymorphism data. *Bioinformatics*. 2009;25:1451-2. <http://dx.doi.org/10.1093/bioinformatics/btp187>
13. **Ma JZ, Beuten J, Payne TJ, Dupont RT, Elston RC, Li MD.** Haplotype analysis indicates an association between the DOPA decarboxylase (DDC) gene and nicotine dependence. *Hum Mol Genet*. 2005;14:1691-8. <http://dx.doi.org/10.1093/hmg/ddi177>
14. **Bedoya G, Montoya P, García J, Soto I, Bourgeois S, Carvajal L, et al.** Admixture dynamics in Hispanics: A shift in the nuclear genetic ancestry of a South American population isolate. *Proc Natl Acad Sci USA*. 2006;103:7234-9. <http://dx.doi.org/10.1073/pnas.0508716103>
15. **Rojas W, Parra MV, Campo O, Caro MA, Lopera JG, Arias W, et al.** Genetic make up and structure of Colombian populations by means of uniparental and biparental DNA markers. *Am J Phys Anthropol*. 2010;143:13-20. <http://dx.doi.org/10.1002/ajpa.21270>
16. **Jiang D, Mummidi S, Ahuja SK, Jarrett HW.** CCR5 promoter haplotype transcription complex characterization. *J Health Care Poor Underserved*. 2011;22(Suppl.):73-90. <http://dx.doi.org/10.1353/hpu.2011.0169>
17. **Mummidi S, Bamshad M, Ahuja SS, González E, Feuillet PM, Begum K, et al.** Evolution of human and non-human primate CC chemokine receptor 5 gene and mRNA. Potential roles for haplotype and mRNA diversity, differential haplotype-specific transcriptional activity, and altered transcription factor binding to polymorphic nucleotides. *J Biol Chem*. 2000;275:18946-61. <http://dx.doi.org/10.1074/jbc.M000169200>
18. **Liu H, Nakayama EE, Theodorou I, Nagai Y, Likanonsakul S, Wasi C, et al.** Polymorphisms in CCR5 chemokine receptor gene in Japan. *Int J Immunogenet*. 2007;34:325-35. <http://dx.doi.org/10.1111/j.1744-313X.2007.00694.x>
19. **Tang J, Shelton B, Makhatadze NJ, Zhang Y, Schaen M, Louie LG, et al.** Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression. *J Virol*. 2002;76:662-72. <http://dx.doi.org/10.1128/JVI.76.2.662-672.2002>
20. **Kawamura T, Gulden FO, Sugaya M, McNamara DT, Borris DL, Lederman MM, et al.** R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. *Proc Natl Acad Sci USA*. 2003;100:8401-6. <http://dx.doi.org/10.1073/pnas.1432450100>
21. **Gong Z, Tang J, Xiang T, Zhang L, Liao Q, Liu W, et al.** Association between regulated upon activation, normal T cells expressed and secreted (RANTES) -28C/G polymorphism and susceptibility to HIV-1 infection: A meta-analysis. *PLoS One*. 2013;8:e60683. <http://dx.doi.org/10.1371/journal.pone.0060683>
22. **He J, Li X, Tang J, Jin T, Liao Q, Hu G.** Association between chemotactic chemokine ligand 5 -403G/A polymorphism and risk of human immunodeficiency virus-1 infection: A meta-analysis. *Onco Targets Ther*. 2015;8:727-34. <http://dx.doi.org/10.2147/OTT.S78581>
23. **Ward LD, Kellis M.** Interpreting noncoding genetic variation in complex traits and human disease. *Nat Biotechnol*. 2012;30:1095-106. <http://dx.doi.org/10.1038/nbt.2422>